A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) With Originator Adalimumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis. J of Skin 2017, 1 (3.1), s29. https://doi.org/10.25251/skin.1.supp.28.